Latest Conference Articles

Tom Kraus, vice president, government affairs for the American Society of Health-System Pharmacists (ASHP) discusses legislators' top concerns with drug pricing and what they're doing to solve the problem. This video was filmed at the ASHP 54th Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada.

The consumption of these antibiotics may lead to dangerous unintended consequences, such as adverse effects that include treatment failures, and antibiotic drug resistance.

Volunteer leaders recognized for advancing mission of sections, new practitioners forum.

Danny Sanchez, VP and general manager of population health services for Omnicell, discusses how technology is bringing pharmacists closer to their patients. This video was filmed at the 2019 ASHP Midyear Clinical Meeting & Exhibition in Las Vegas.

Immunotherapy drug blinatumomab showed benefit in pediatric patients with relapsed acute lymphoblastic leukemia who have minimal residual disease following chemotherapy.

A combination therapy of carfilzomib, dexamethasone, and daratumumab extended progression-free survival when compared with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

An oral formulation of azacitidine improved overall survival in patients with acute myeloid leukemia in first remission.

In addition to handling issues such as depression, post-traumatic stress disorder, suicide screenings, and anxiety, many mental health pharmacists deal with typical metabolic conditions, such as hypertension and diabetes.

Lisa Dumkow, PharmD, BCIDP, a clinical pharmacist of antimicrobial stewardship, discusses outpatient stewardship and why it's vital for health system pharmacists. This video was filmed at the 2019 ASHP Midyear Meeting Clinical Meeting & Exhibition in Las Vegas.

The current observational, longitudinal study focused on patient-reported outcomes on functioning, symptoms, and quality of life in patients with chronic lymphocytic leukemia.

Four healthcare practitioners have been recognized by the American Society of Health-System Pharmacists (ASHP) with different leadership awards. The honorees were presented with the awards during specific ceremonies at the ASHP Midyear Clinical Meeting and Exhibition in Las Vegas.

A pharmacy-driven assessment found more than half of patients with reported penicillin allergies were able to take antibiotics from the same drug class, rather than resorting to substitutes that may have downsides.

Check the Pharmacy Times® website for more information and be sure to watch for daily newsletters, online conference articles and videos, and social media updates.

A poster presented at the American Society of Hematology Annual Meeting and Exposition assessed disease-related health care utilization and costs among patients with multiple myeloma.

The award recognizes pharmacists who demonstrate leadership and innovation in enhancing patient care and other areas of pharmacy practice.

Formulary management tools can seem daunting or frustrating, but are ultimately effective ways to control costs without compromising clinical outcomes.

In a session at the American Society of Hematology Annual Meeting and Exposition, held December 7-10 in Orlando, Florida, experts presented on the evolution of CLL therapy, how to make treatment decisions, and what’s to come in the future based on ongoing studies.

Population migration to more urban locales, and rural hospital closures are some factors increasing the challenges of health care access to patients and pharmacists in remote areas of the country. Innovation advocated by the National Rural Health Association (NRHA) may provide keys to improving access to health care services.

Jennifer Woyach, MD, associate professor at The Ohio State University, gives an overview of the new data in chronic lymphocytic leukemia being presented at the 2019 American Society of Hematology Annual Meeting and Exposition.

Jennifer Woyach, MD, associate professor at The Ohio State University, discusses current clinical trials going on in the chronic lymphocytic leukemia space that are most likely to impact the treatment landscape.

Jennifer Woyach, MD, associate professor at The Ohio State University, explains how patient-specific factors can help determine treatment decisions in chronic lymphocytic leukemia.

Jeffrey Fudin, PharmD, DAIPM, FASHP, FFSMB, CEO of Remitigate, discusses how opioid and pain management guidelines have evolved. This video was filmed at the 2019 ASHP Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada.

The study evaluated lymphoma characteristics and outcomes in hepatitis C virus-associated B-cell non-Hodgkin lymphoma in African American patients.

A novel, off-the-shelf bispecific antibody could serve as a new treatment option for patients with non-Hodgkin lymphoma who don’t respond to CAR T-cell therapy.

A study looked at adherence rates and potential predictors of nonadherence in patients with hemophilia receiving emicizumab.

The analysis evaluated emerging mutations in patients with relapsed/refractory acute myeloid leukemia receiving gilteritinib therapy in the phase 3 ADMIRAL study.

A prospective analysis of the CLL14 trial showed that fixed-duration treatment of venetoclax plus obinutuzumab achieved high rates of undetectable minimal residual disease.

Patients receiving novel oral therapeutics often have a high dependence on financial assistance; specialty pharmacies may help facilitate access to these therapies.